(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Pick Your Favored kind of salad - 2Experts who once backed 'shaken baby' science now fight to free imprisoned caregivers
- 3Commonsense Ways to work on Your Funds with a Restricted Pay
- 4$2,000 tariff rebate checks? 50-year mortgages? Making sense of Trump's new 'affordability' proposals.
- 5I took my shoes off and went for a barefoot hike. I couldn’t believe what happened next
- Remote Headphones: Improve Your Sound Insight
- Israeli lawmakers pass bill reviving death penalty for terrorists
- Tear gas and arrests: Iranian regime continues crackdown on protesters amid economic unrest
- Israeli police block Latin Patriarch from Palm Sunday mass in Jerusalem
- Help Your Efficiency with These Work area Updates
- The Electric Bicycle Americans Can Confide in 2024
- Korean Air takes emergency action as fuel prices soar
- Struggling to keep your New Year's resolutions? Here's how to keep yourself on track
- Remote Headphones: Upgrade Your Sound Insight
